Shire's Adderall bows out in style ahead of generic introduction
30 April 2009
Simon Varcoe
Please Login to read the full article.
30 April 2009
Simon Varcoe
simon.varcoe@informa.com
Shire's first quarter revenues increased by 17% to $817.8 million on a US GAAP basis.
The biopharmaceutical company's attention deficit hyperactivity disorder (ADHD) treatment Vyvanse (lisdexatetamine dimesylate) continued to drive growth, with sales more than doubling to $116.6 million....
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
